CO2023011623A2 - fgfr3 inhibitory compounds - Google Patents
fgfr3 inhibitory compoundsInfo
- Publication number
- CO2023011623A2 CO2023011623A2 CONC2023/0011623A CO2023011623A CO2023011623A2 CO 2023011623 A2 CO2023011623 A2 CO 2023011623A2 CO 2023011623 A CO2023011623 A CO 2023011623A CO 2023011623 A2 CO2023011623 A2 CO 2023011623A2
- Authority
- CO
- Colombia
- Prior art keywords
- inhibitory compounds
- fgfr3 inhibitory
- achondroplasia
- fibrosis
- fgfr3
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 101150025764 FGFR3 gene Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 208000008919 achondroplasia Diseases 0.000 abstract 3
- 201000001079 SADDAN Diseases 0.000 abstract 2
- 208000017601 Severe achondroplasia-developmental delay-acanthosis nigricans syndrome Diseases 0.000 abstract 2
- 206010008723 Chondrodystrophy Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 208000007326 Muenke Syndrome Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000009594 Systemic Scleroderma Diseases 0.000 abstract 1
- 206010042953 Systemic sclerosis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 201000003896 thanatophoric dysplasia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención proporciona los compuestos de la fórmula: , para usar en el tratamiento de la esclerosis sistémica, la fibrosis (p. ej., fibrosis pulmonar), la acondroplasia, la displasia tanatofórica (p. ej., tipo I), la acondroplasia grave con retraso del desarrollo y acantosis nigricans (SADDAN), el síndrome de Muenke o el cáncer.The present invention provides compounds of the formula: , for use in the treatment of systemic sclerosis, fibrosis (e.g., pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g., type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), Muenke syndrome or cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163156527P | 2021-03-04 | 2021-03-04 | |
| PCT/US2022/018644 WO2022187443A1 (en) | 2021-03-04 | 2022-03-03 | Fgfr3 inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023011623A2 true CO2023011623A2 (en) | 2023-09-18 |
Family
ID=80937162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0011623A CO2023011623A2 (en) | 2021-03-04 | 2023-09-01 | fgfr3 inhibitory compounds |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11878976B2 (en) |
| EP (1) | EP4301468A1 (en) |
| JP (1) | JP7480438B2 (en) |
| KR (1) | KR20230130170A (en) |
| CN (1) | CN117120439A (en) |
| AR (1) | AR125588A1 (en) |
| AU (1) | AU2022229380A1 (en) |
| BR (1) | BR112023015519A2 (en) |
| CA (1) | CA3210594A1 (en) |
| CO (1) | CO2023011623A2 (en) |
| CR (1) | CR20230427A (en) |
| DO (1) | DOP2023000176A (en) |
| EC (1) | ECSP23066654A (en) |
| IL (1) | IL304886A (en) |
| MX (1) | MX2023010342A (en) |
| PE (1) | PE20231563A1 (en) |
| TW (2) | TWI820622B (en) |
| WO (1) | WO2022187443A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024054814A1 (en) | 2022-09-07 | 2024-03-14 | Eli Lilly And Company | Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxy-ethoxy]pyrazolo[1,5-a]pyridin-6-yl]-5-methyl- triazol-1-yl]piperidine-1 -carbonitrile derivatives with gallic acid and nicotine amide |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| WO2024117205A1 (en) * | 2022-11-30 | 2024-06-06 | 北興化学工業株式会社 | Bicyclic pyridine derivative and salt thereof, and harmful organism control agent characterized by containing said derivative or salt thereof as active ingredient |
| WO2024114680A1 (en) * | 2022-11-30 | 2024-06-06 | 海南先声再明医药股份有限公司 | Heterocyclic compound, pharmaceutical composition, and application thereof |
| WO2024137587A1 (en) * | 2022-12-19 | 2024-06-27 | Tyra Biosciences, Inc. | Fgfr3 inhibitor compounds |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011530511A (en) | 2008-08-05 | 2011-12-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Therapeutic compounds |
| KR102283091B1 (en) | 2010-03-10 | 2021-07-30 | 인사이트 홀딩스 코포레이션 | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| CN101833512A (en) | 2010-04-22 | 2010-09-15 | 中兴通讯股份有限公司 | Method and device thereof for reclaiming memory |
| RU2014118954A (en) | 2011-10-12 | 2015-11-20 | Эррэй Биофарма Инк. | 5,7-SUBSTITUTED-IMIDAZO [1,2-c] pyrimidines |
| NZ703495A (en) | 2012-07-11 | 2018-02-23 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| MX2016001427A (en) | 2013-07-31 | 2016-08-03 | Gilead Sciences Inc | Syk inhibitors. |
| GB201416754D0 (en) * | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| CR20170390A (en) * | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | BICYCLE HETEROCICLES AS FGFR INHIBITORS |
| MX370933B (en) | 2015-04-29 | 2020-01-09 | Wuxi Fortune Pharmaceuticals Co Ltd | Jak inhibitors. |
| EP3298011B1 (en) | 2015-05-22 | 2021-11-17 | Principia Biopharma Inc. | Quinolone derivatives as fibroblast growth factor receptor inhibitors |
| EP3508482B1 (en) | 2016-09-01 | 2020-12-16 | Nanjing Transthera Biosciences Co. Ltd. | Inhibitors of fibroblast growth factor receptor and use thereof |
| CN107315291B (en) | 2017-07-19 | 2020-06-16 | 深圳市华星光电半导体显示技术有限公司 | GOA display panel and GOA display device |
| EP3668858A1 (en) | 2017-08-14 | 2020-06-24 | Pfizer Inc | Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives |
| JP2022515198A (en) * | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | Substituted pyrazolo [1,5-a] pyridine compound as an inhibitor of FGFR tyrosine kinase |
-
2022
- 2022-03-02 TW TW111107515A patent/TWI820622B/en active
- 2022-03-02 TW TW112137198A patent/TW202402754A/en unknown
- 2022-03-02 AR ARP220100462A patent/AR125588A1/en unknown
- 2022-03-03 JP JP2023530844A patent/JP7480438B2/en active Active
- 2022-03-03 EP EP22712686.9A patent/EP4301468A1/en active Pending
- 2022-03-03 AU AU2022229380A patent/AU2022229380A1/en active Pending
- 2022-03-03 MX MX2023010342A patent/MX2023010342A/en unknown
- 2022-03-03 CA CA3210594A patent/CA3210594A1/en active Pending
- 2022-03-03 KR KR1020237029713A patent/KR20230130170A/en not_active Application Discontinuation
- 2022-03-03 PE PE2023002463A patent/PE20231563A1/en unknown
- 2022-03-03 WO PCT/US2022/018644 patent/WO2022187443A1/en active Application Filing
- 2022-03-03 BR BR112023015519A patent/BR112023015519A2/en unknown
- 2022-03-03 CN CN202280019076.1A patent/CN117120439A/en active Pending
- 2022-03-03 US US17/685,753 patent/US11878976B2/en active Active
- 2022-03-03 CR CR20230427A patent/CR20230427A/en unknown
- 2022-03-03 IL IL304886A patent/IL304886A/en unknown
-
2023
- 2023-09-01 CO CONC2023/0011623A patent/CO2023011623A2/en unknown
- 2023-09-01 DO DO2023000176A patent/DOP2023000176A/en unknown
- 2023-09-04 EC ECSENADI202366654A patent/ECSP23066654A/en unknown
- 2023-12-13 US US18/538,505 patent/US20240190870A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023015519A2 (en) | 2023-10-03 |
| JP7480438B2 (en) | 2024-05-09 |
| WO2022187443A1 (en) | 2022-09-09 |
| PE20231563A1 (en) | 2023-10-03 |
| IL304886A (en) | 2023-10-01 |
| MX2023010342A (en) | 2023-09-15 |
| CA3210594A1 (en) | 2022-09-09 |
| US20230095122A1 (en) | 2023-03-30 |
| TW202300491A (en) | 2023-01-01 |
| DOP2023000176A (en) | 2023-09-29 |
| EP4301468A1 (en) | 2024-01-10 |
| US20240190870A1 (en) | 2024-06-13 |
| AR125588A1 (en) | 2023-08-02 |
| TWI820622B (en) | 2023-11-01 |
| KR20230130170A (en) | 2023-09-11 |
| JP2023554598A (en) | 2023-12-28 |
| ECSP23066654A (en) | 2024-02-29 |
| TW202402754A (en) | 2024-01-16 |
| CN117120439A (en) | 2023-11-24 |
| CR20230427A (en) | 2023-09-26 |
| AU2022229380A1 (en) | 2023-08-24 |
| US11878976B2 (en) | 2024-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023011623A2 (en) | fgfr3 inhibitory compounds | |
| CL2019003394A1 (en) | Kras g12c inhibitors and methods for their use. | |
| EA201990615A1 (en) | Pyrrolobenzodiazepine conjugates | |
| ECSP19042682A (en) | 7-PHENYLETHYLAMINE-4H-PYRIMIDE [4,5-D] [1,3] -OXAZIN-2-ONA COMPOUNDS AS INHIBITORS OF IDH1 AND IDH2 MUTANTS | |
| CL2022002978A1 (en) | 2,4-dioxopyrimidine compounds inhibitors of cd73 | |
| EA202191800A1 (en) | AZHETEROBYCLIC MAT2A INHIBITORS AND METHODS OF THEIR APPLICATION FOR TARGETING ON CANCER | |
| PH12020551464A1 (en) | Cd73 inhibitors | |
| AR099854A1 (en) | DERIVATIVES OF QUINAXOLINE WITH ACTION ON TYROSINKINES | |
| EA202092263A1 (en) | AMINOPYRIDINE DERIVATIVES AS CTPS1 INHIBITORS | |
| MX2021004659A (en) | Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors. | |
| UY38999A (en) | PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE OF THE SAME | |
| CL2020000950A1 (en) | Enhancer for t cells or b cells having memory function, malignant tumor recurrence inhibitor, and inducer to induce memory function in t cells or b cells. | |
| CL2020001719A1 (en) | P38 kinase inhibitors that reduce expression of dux4 and downstream genes for the treatment of fshd (divisional application 202000911) | |
| CL2019002854A1 (en) | Macrocyclic compound and its uses. | |
| EA202191557A1 (en) | COMBINED THERAPY WITH RADIOIMMUNOCONJUGATES AND DNA DAMAGE REPAIR INHIBITORS | |
| BR112017022807A2 (en) | ? electric submersible pump, and, electric submersible pump column? | |
| PH12019501893A1 (en) | Methods for increasing blood plasma 2`-deoxyuridine (durd) and thymidylate synthase inhibition | |
| CO2019005165A2 (en) | Pyridone compound as c-met inhibitor | |
| EA201691566A1 (en) | APPLICATION OF PYRIDAZIN DERIVATIVES FOR THE PREVENTION OR TREATMENT OF THE ATTAXIC SYNDROME | |
| MX2021001870A (en) | Method for treating pancreatic cancer. | |
| EA202191180A1 (en) | CONDENSED HETEROCYCLIC BENZODIAZEPINE DERIVATIVES AND THEIR APPLICATION | |
| CU20190019A7 (en) | COMBINATIONS INCLUDING ABX196 USEFUL IN THE TREATMENT OF CANCER | |
| AR112217A1 (en) | A COMBINATION OF AN INHIBITOR OF MPS1 AND A COMPOUND TAXAN, USES AND PHARMACEUTICAL COMPOSITIONS OF THE latter | |
| TH1901002609A (en) | Pyridone compounds as C-MET inhibitors | |
| BR112022020295A2 (en) | COMPOUNDS FOR THE TREATMENT OF SARS |